SCV-KTx-imm: Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) Immune Kidney Transplant Study (COVID-19)
Study Details
Study Description
Brief Summary
None of the vaccines approved, or in clinical trials, have so far been tested on transplanted patients. If they produce an immune response to the Spike protein of SARS-CoV-2 it is unknown how long the protective immunity will last.
Not all immune responses are equal. The investigators will quantify immune cell subsets with flow and mass cytometry analyses to describe the phenotype of responding immune cells, including specific T cells. If not already established, patient human Leukocyte antigen (HLA) genotypes will be typed.
In order to compare the immune responses with healthy individuals a control group of hospital employees will be included and sampled before and after vaccination according to the same time schedules as the kidney transplanted patients.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
Kidney transplanted patients with post-transplant follow-up visits at the national transplant center in Norway will be included before they are SARS-CoV-2 vaccinated. As a control group the investigators will include blood samples from healthy volunteers (hospital employees) that receive vaccine as first line health care workers.
Baseline blood samples will be obtained before vaccination. The vaccination will be performed according to the national procedures and not necessarily by the hospital. Following vaccination, all patients and controls will have blood drawn 7-10 days as well as 4-6 weeks after the second dose. Depending on the results of the immunity testing the patients and controls may be invited to additional blood sampling up or at specific time points to two years following vaccination.
At each blood sampling and at the time of both vaccinations the systemic exposure of tacrolimus will be assessed in kidney transplanted patients.
All samples will be analyzed with validated assays for SARS-CoV-2 immunoglobulin G (IgG) (anti-receptor binding domain (RBD) spike protein) using ELISA, flow cytometry bead arrays and SARS-CoV-2 neutralization assays or comparable techniques. Cells will be analyzed by flow and mass cytometry for activation and phenotype markers, and with functional assays for responsiveness (e.g. proliferation and cytokine production). Samples will be HLA-typed if HLA-genotype if not already established.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Kidney Transplanted patients Kidney transplanted patients transplanted at least 6 months prior to SARS-CoV-2 vaccination. Vaccination according to national plan with messenger Ribonucleic acid (mRNA) vaccine |
Drug: SARS-CoV-2 vaccine
SARS-CoV-2 vaccines currently on market, i.e. Pfizer/BioNTech and Moderna
|
| Healthy controls Healthy hospital staff receiving SARS-CoV-2 mRNA vaccine as being front line Healthcare workers. |
Drug: SARS-CoV-2 vaccine
SARS-CoV-2 vaccines currently on market, i.e. Pfizer/BioNTech and Moderna
|
Outcome Measures
Primary Outcome Measures
- Cellular immunological response [1.5 months]
IgG antibodies against SARS-CoV-2 spike protein above assay limit of positive sample.
- Humoral immunological response [1.5 months]
T-cell reactivity against SARS-CoV-2 spike protein, including known mutation in the spike protein.
Secondary Outcome Measures
- Vaccine related side effects [6 months]
Adverse drug reactions that have a reasonable relation to the vaccination, as assessed by the investigator
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patients transplanted with a kidney (only) at least 6 months before vaccination OR healthy volunteer first line health care workers at OUS.
-
Age of 18 years or older (also for controls).
-
Standard immunological risk at transplantation (i.e. no donor specific HLA antibodies (DSA)) and not performed an ABO blood-type-incompatible transplantation.
-
No treatment for rejection episodes the last 6 months before inclusion.
-
Immunosuppressive therapy including tacrolimus, mycophenolate and prednisolone.
-
Stable graft-function the last 6 months.
-
S-creatinine < 200 μmol/L (also for controls).
-
Signed informed consent to participate in the study (also for controls).
Exclusion Criteria:
-
Three or more previous transplantations.
-
Hemoglobin level below 10 g/dL (also for control).
-
Leukopenia defined as total lymphocyte count < 2 X 109 (also for controls).
-
Previous treatment with anti-thymocyte antibodies (ATG) or rituximab.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Oslo University Hospital | Oslo | Norway | 0424 |
Sponsors and Collaborators
- Oslo University Hospital
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 227626